Dronabinol (Marinol) for Appetite Stimulation in Dementia
Dronabinol should NOT be used to stimulate appetite in elderly patients with dementia who are losing weight, as current guidelines explicitly recommend against appetite stimulants in this population due to lack of consistent efficacy and potential for harm. 1
Guideline Recommendations Against Use
The 2024 ESPEN guideline on nutrition and hydration in dementia provides clear direction:
- Drugs to stimulate appetite or weight gain should NOT be used in persons with dementia 1
- This recommendation achieved 89% expert consensus 1
- The rationale is based on trials with weak methodology that failed to achieve consistent effects on appetite and body weight 1
- Potentially harmful side effects must be balanced against very uncertain benefits 1
Evidence Base for This Recommendation
Cannabinoid Studies in Dementia
- Only three small placebo-controlled trials (total n=100) have investigated cannabinoids for weight change or caloric intake in dementia patients 1
- A Cochrane Review found no significant effect on body weight, BMI, or energy intake from cannabinoids in dementia 1
- A 2021 systematic review concluded there is no convincing evidence for THC in dementia, rating the evidence quality as low to very low 2
Safety Concerns in Elderly Dementia Patients
The FDA labeling highlights specific risks that are particularly concerning in this population:
- Elderly patients, especially those with dementia, have increased risk of psychiatric symptoms, changes in blood pressure, and falls 3
- CNS adverse reactions include feeling high, dizziness, confusion, and somnolence 3
- Psychiatric symptoms can worsen in people with mania, depression, or schizophrenia 3
- Hemodynamic instability including hypotension, hypertension, syncope, and tachycardia may occur 3
FDA-Approved Indication vs. Off-Label Use
While dronabinol is FDA-approved for anorexia associated with weight loss in AIDS patients, this indication does not extend to dementia:
- FDA-approved starting dose for AIDS-related anorexia: 2.5 mg orally twice daily, one hour before lunch and dinner 3
- For elderly patients unable to tolerate this dose, consider 2.5 mg once daily in the evening or at bedtime 3
- Maximum dosage: 10 mg twice daily 3
However, the AIDS population differs fundamentally from elderly dementia patients in terms of risk-benefit profile 1
Limited Positive Evidence
Some older, small studies showed modest effects, but these do not override guideline recommendations:
- A 1997 study (n=12 completers) showed weight gain and decreased behavioral disturbances, but had significant methodological limitations 4
- A 2007 retrospective study (n=28) showed 53.5% gained weight, but those who lost weight had higher mortality (64% vs 26%) 5
- A 2014 retrospective chart review (n=40) focused on agitation, not appetite 6
- A 2026 trial showed efficacy for agitation but did not demonstrate appetite or weight benefits 7
Alternative Approaches
Rather than pharmacological appetite stimulation, focus on:
- Nutritional assessment and personalized interventions 8
- Multidisciplinary team approach with monitoring of diet and education 8
- Addressing underlying causes of weight loss (dental problems, swallowing difficulties, depression) 1
- Vitamin supplementation for those consuming <1500 kcal/day 8
- If depression coexists with anorexia, mirtazapine may provide dual benefit (though evidence in dementia is limited to one small retrospective study) 1
Clinical Pitfall to Avoid
Do not assume that FDA approval for AIDS-related anorexia translates to efficacy or safety in elderly dementia patients—the evidence specifically contradicts this extrapolation 1, 2